New blood thinner may simplify life after valve replacement
NCT ID NCT04258488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a newer blood thinner (rivaroxaban) works as well as the standard drug (warfarin) for preventing clots and bleeding in people who have a mechanical aortic valve. About 1,300 adults who had valve surgery at least 3 months ago will take one of the two pills daily for a year. The goal is to see which drug better prevents serious heart problems and bleeding complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (oral blood thinner)
What this could lead to
If successful, this could offer a simpler, more predictable blood-thinning option for people with mechanical aortic valves, potentially reducing the need for frequent blood tests.
What could go wrong
This is a phase 4 trial, so the drug is already approved for other uses, but its safety and effectiveness for this specific valve type are not yet proven. There is a risk of bleeding or clotting events.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
RECRUITINGSuwon, South Korea
Contact
Contact
-
Asan Medical Center
RECRUITINGSeoul, 138-736, South Korea
Contact
Contact
-
Buchen Sejong Hospital
RECRUITINGBucheon-si, South Korea
Contact
Contact
-
Chonnam National University Hospital
RECRUITINGGwangju, South Korea
Contact
Contact
-
Dong-A University Hospital
RECRUITINGBusan, South Korea
Contact
Contact
-
Eulji University Uijeongbu Hospital
RECRUITINGUijeongbu-si, South Korea
Contact
Contact
-
GangNeung Asan Hospital
RECRUITINGGangneung, South Korea
Contact
Contact
-
Keimyung University Dongsan Hospital
RECRUITINGDaegu, South Korea
Contact
Contact
-
Korea University Anam Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
-
Pusan National University Yangsan Hospital
RECRUITINGYangsan, South Korea
Contact
Contact
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact
Contact
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, South Korea
Contact
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact
Contact
-
Severance Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
Contact
-
St. Vincent's Hospital, Catholic University of Korea
NOT_YET_RECRUITINGSuwon, South Korea
Contact
Contact
-
Ulsan University Hospital
NOT_YET_RECRUITINGUlsan, South Korea
Contact
Contact